Wendy Latash explains how a desire to satisfy the needs of the patient inspired AONN+ and Astellas to collaborate on the creation of the AONN+ Acuity Tool.
Prostate cancer (PCa) patients treated with injectable androgen deprivation therapy (ADT) are particularly vulnerable during a pandemic because they may not be able to self-administer treatment and may be required to visit a clinic/hospital for injections.
Prostate cancer is the most common male malignancy. In 2021, the United States will see an estimated 248,530 new cases, 34,130 deaths, and more than 3 million survivors.